Presti J C, Hinckley J, Reuter V E
Department of Urology, University of California, San Francisco 94143-0738, USA.
Cancer Genet Cytogenet. 1996 May;88(1):66-8. doi: 10.1016/0165-4608(95)00275-8.
The L-MYC restriction fragment-length polymorphism (RFLP) revealed by EcoR1 has been suggested to be of prognostic significance in lung, breast, and kidney cancer. The presence of the smaller allele, in either the homozygotic (S-S) or heterozygotic form (L-S), is felt to convey a worse prognosis than the homozygotic form for the larger allele (L-L). The significance of this relationship in lung cancer has been questioned recently. The objective of the present study was to test the prognostic significance of the L-MYC allelotype in a group of renal cell carcinoma (RCC) patients. Tumor and normal tissue were obtained from 59 patients who underwent radical nephrectomy for RCC between 1986 and 1990. EcoR1 restriction digests were performed on isolated DNA and hybridized with the L-MYC probe. Allelotypes were correlated with pathologic parameters and clinical outcome using the chi 2 test. The L-MYC alleolotype (L-L versus L-S and S-S) did not correlate with any pathologic parameter or likelihood of disease recurrence and does not offer any clinical utility in patients with RCC.
由EcoR1揭示的L-MYC限制性片段长度多态性(RFLP)已被认为在肺癌、乳腺癌和肾癌中具有预后意义。纯合子(S-S)或杂合子形式(L-S)中较小等位基因的存在,被认为比纯合子形式的较大等位基因(L-L)预后更差。最近,这种关系在肺癌中的意义受到了质疑。本研究的目的是测试L-MYC等位基因型在一组肾细胞癌(RCC)患者中的预后意义。从1986年至1990年间因RCC接受根治性肾切除术的59例患者中获取肿瘤组织和正常组织。对分离出的DNA进行EcoR1限制性酶切,并与L-MYC探针杂交。使用卡方检验将等位基因型与病理参数和临床结果相关联。L-MYC等位基因型(L-L与L-S和S-S)与任何病理参数或疾病复发可能性均无相关性,并且对RCC患者没有任何临床实用价值。